Iambic Therapeutics

aid: iambic
url: https://raw.githubusercontent.com/api-evangelist/iambic/refs/heads/main/apis.yml
name: Iambic Therapeutics
type: Index
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/iambic.png
description: Iambic Therapeutics is a clinical-stage AI drug discovery company headquartered in San Diego. Its proprietary
  AI platform pairs the NeuralPLexer 3D generative model for protein-ligand structure prediction with the Enchant multimodal
  transformer for clinical and preclinical endpoint prediction, integrated with automated wet-lab capabilities. Iambic's clinical
  pipeline includes IAM1363 (HER2), IAM-K1 (KIF18A), and IAM-C1 (CDK2/4) in oncology. Iambic is a therapeutics developer rather
  than an API provider and does not publish a public developer API or open-source platform.
tags:
- Drug Discovery
- AI for Science
- Therapeutics
- Biotech
- Oncology
- Clinical-Stage Pipeline
- Generative Chemistry
- Structural Biology
created: '2026-05-23'
modified: '2026-05-23'
specificationVersion: '0.23'
apis: []
common:
- type: DomainSecurity
  url: security/iambic-domain-security.yml
- type: Website
  url: https://www.iambic.ai/
- type: Pipeline
  url: https://www.iambic.ai/pipeline
- type: Platform
  url: https://www.iambic.ai/platform
- type: Newsroom
  url: https://www.iambic.ai/news
- type: Publications
  url: https://www.iambic.ai/publications
- type: Careers
  url: https://www.iambic.ai/careers
- type: Contact
  url: https://www.iambic.ai/contact
- type: Email
  url: mailto:contact@iambic.ai
- type: LinkedIn
  url: https://www.linkedin.com/company/iambictherapeutics
- type: Twitter
  url: https://twitter.com/iambictx
- url: https://www.iambic.ai/news
  type: Blog
- type: Features
  data:
  - name: NeuralPLexer
    description: 3D generative model that predicts protein-ligand complex structures directly from amino acid sequence and
      ligand graph inputs, reported in Nature Machine Intelligence with state-of-the-art docking and binding-site performance.
  - name: Enchant
    description: Multimodal transformer that predicts clinical and preclinical endpoints from molecular structures.
  - name: Automated Wet-Lab Integration
    description: Closed-loop coupling of AI design with high-throughput automated wet-lab synthesis and assay capabilities.
  - name: Brain-Penetrant Small Molecules
    description: Programs such as IAM1363 designed to cross the blood-brain barrier for CNS and brain-metastatic oncology
      indications.
- type: Pipeline
  data:
  - name: IAM1363 (HER2)
    description: Brain-penetrant HER2 inhibitor showing anti-tumor activity in Phase 1b clinical trials.
  - name: IAM-K1 (KIF18A)
    description: Potential best-in-class KIF18A inhibitor for breast and ovarian cancers.
  - name: IAM-C1 (CDK2/4)
    description: Selective CDK2/4 inhibitor for HR+/HER2- metastatic breast cancer.
- type: UseCases
  data:
  - name: AI-Driven Small-Molecule Design
    description: End-to-end design of novel small-molecule therapeutics using generative AI.
  - name: Protein-Ligand Structure Prediction
    description: Structural prediction to support hit discovery and lead optimization.
  - name: Clinical Endpoint Prediction
    description: Machine-learning prediction of preclinical and clinical endpoints to guide program selection.
- type: Partnerships
  data:
  - name: Takeda
    description: Multi-year collaboration announced February 2026 to apply Iambic's AI-driven drug discovery platform to Takeda's
      small-molecule R&D in oncology, gastrointestinal, and inflammation. Includes an undisclosed upfront payment plus research
      funding, with up to $1.7B in development and sales milestones and royalties on resulting products.
- type: Recognition
  data:
  - name: CNBC Disruptor 50
    description: Named to the CNBC Disruptor 50 list.
  - name: Conference Presentations
    description: Presented at industry conferences including the JPMorgan Healthcare Conference, Galien Forum, and AIAS.
- type: Authentication
  data:
  - name: No Public Developer API
    description: Iambic Therapeutics does not publish a public developer API, SDK, or open-source platform. Engagement is
      through pharma partnerships and the company's internal R&D pipeline.
- type: Compliance
  data:
  - name: GxP Drug Development
    description: Operates within standard pharmaceutical regulatory frameworks (GLP, GMP, GCP) for clinical-stage drug development.
- type: Facilities
  data:
  - name: San Diego Headquarters
    description: Headquartered in San Diego, California with AI, computational chemistry, and automated wet-lab facilities.
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com